SCHEMBL23932502

SCHEMBL23932502

Cc1ncnc(N2CCN(Cc3nc4cc(C(F)(F)F)ccc4o3)CC2)c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 2/20 0.42
CNR2 P34972 1/20 0.42
HRH4 Q9H3N8 3/20 0.41
RBP4 P02753 1/20 0.41
GRM2 Q14416 2/20 0.40
AKR1B1 P15121 1/20 0.39
LMNA P02545 2/20 0.38
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TRPV1 Q8NER1 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
PIK3CA P42336 1/20 0.37
MTOR P42345 1/20 0.37
TP53 P04637 1/20 0.37
MAOA P21397 1/20 0.37
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30040810 1.00 RPS6KB1 (0.42) RPS6KB1CNR2HRH4RBP4GRM2
SCHEMBL30040088 0.93 RPS6KB1 (0.44) RPS6KB1HRH4RBP4GRM2LMNA
SCHEMBL23932507 0.93 RPS6KB1 (0.44) RPS6KB1HRH4RBP4GRM2LMNA
SCHEMBL30040150 0.87 KDM4E (0.45) LMNAALDH1A1HTTSMN1; SMN2KDM4E
SCHEMBL23932546 0.87 KDM4E (0.45) LMNAALDH1A1HTTSMN1; SMN2KDM4E
SCHEMBL23964257 0.85 SOS1 (0.47) RPS6KB1HRH4LMNAALDH1A1HTT
SCHEMBL25505769 0.84 CACNA1G (0.38) LMNAALDH1A1HTTSMN1; SMN2KDM4E
SCHEMBL23932495 0.83 MAPK1 (0.46) LMNAALDH1A1HTTSMN1; SMN2KDM4E
SCHEMBL30041262 0.83 MAPK1 (0.46) LMNAALDH1A1HTTSMN1; SMN2KDM4E
SCHEMBL31738151 0.82 TP53 (0.41) RPS6KB1LMNAALDH1A1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
EP-4139291-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF Anima Biotech Inc. (US) 2023-03-01 EP disclosed
CN-115427404-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2022-12-02 CN disclosed
WO-2021216665-A9 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-12-02 WO disclosed
WO-2021216665-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-10-28 WO disclosed
WO-2021216665-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 RPS6KB1 316/4885CNR2 4661/4885HRH4 4471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.